

**Idiopathic inflammatory myopathies: new therapeutic horizons**

Campanilho-Marques R<sup>1</sup>

<sup>1</sup>Rheumatology Department, Unidade Local de Saúde Santa Maria, Lisbon, Portugal; Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal

**Correspondence to**

Raquel Campanilho-Marques

E-mail: raquelpcmarques@gmail.com

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article'

© 2026 Portuguese Society of Rheumatology

This article is protected by copyright. All rights reserved.

Idiopathic inflammatory myopathies (IIM) constitute a heterogeneous group of rare autoimmune disorders characterised by chronic muscle inflammation, progressive weakness and a broad spectrum of extra-muscular manifestations<sup>1</sup>. Despite substantial advances in immunology and disease classification over the past two decades, the management of these conditions remains challenging. Therapeutic strategies continue to rely heavily on empirical approaches, reflecting both the rarity of the diseases and the limited availability of robust clinical trial data<sup>2,3</sup>.

For many years, glucocorticoids have remained the cornerstone of treatment. Their rapid anti-inflammatory effect makes them indispensable in the initial control of disease activity. However, prolonged corticosteroid use carries well-recognized risks, including metabolic complications, infection, osteoporosis and cardiovascular morbidity. As a result, the need for effective steroid-sparing strategies has become increasingly apparent. In clinical practice, conventional immunosuppressive agents such as methotrexate, azathioprine and mycophenolate mofetil are frequently introduced early in the disease course to facilitate glucocorticoid tapering and improve long-term outcomes<sup>4,5</sup>.

While these therapies remain widely used, their efficacy varies considerably between patients and across disease subsets. Moreover, their use is often supported more by clinical experience than by high-quality evidence<sup>6</sup>. The relative scarcity of randomised controlled trials in IIM continues to represent a major limitation in guiding treatment decisions<sup>7</sup>. Consequently, clinicians are frequently required to rely on observational data, small cohort studies and expert consensus when tailoring therapy to individual patients.

In recent years, the therapeutic landscape of IIM has begun to evolve, driven by advances in disease characterisation and a better understanding of immunopathological mechanisms. One of the most significant developments has been the increasing use of intravenous immunoglobulin (IVIG)<sup>8</sup>. Evidence supporting the efficacy of IVIG has strengthened considerably, particularly following the results of controlled clinical trials demonstrating meaningful improvements in muscle strength and overall disease activity in dermatomyositis<sup>9</sup>. These findings have led to regulatory approval of IVIG for dermatomyositis in several jurisdictions and have reinforced its role as an important therapeutic option, particularly in patients with refractory disease or intolerance to conventional immunosuppressants.

Beyond its effects on muscle involvement, IVIG may also provide benefits in selected extra-muscular manifestations, including severe cutaneous disease and dysphagia<sup>10</sup>. Nevertheless, questions remain regarding optimal dosing strategies, duration of therapy and long-term cost-effectiveness. Given the high economic burden associated with IVIG treatment, careful patient selection and ongoing evaluation of therapeutic response are essential.

Parallel to these developments, biologic therapies have increasingly attracted attention as potential targeted treatments for IIM. Among these, B-cell depletion with rituximab has been one of the most extensively studied approaches<sup>11</sup>. Although the results of large clinical trials have been somewhat inconclusive, subsequent analyses and real-world studies suggest that certain patient subsets may derive significant benefit, particularly those with specific myositis-related autoantibodies or severe refractory disease<sup>12</sup>. These observations underscore the importance of recognising the immunological heterogeneity of IIM and suggest that future therapeutic strategies may need to be guided by more refined patient stratification.

Other biologic agents are also being explored. T-cell co-stimulation blockade with abatacept has shown encouraging signals in early studies, reflecting the central role of adaptive immune mechanisms in the pathogenesis of inflammatory myopathies<sup>13</sup>. Although further clinical trials are needed to clarify its efficacy, such approaches illustrate the growing interest in therapies targeting specific immune pathways rather than relying solely on broad immunosuppression. More recently, small-molecule inhibitors have emerged as promising additions to the therapeutic armamentarium. In particular, Janus kinase (JAK) inhibitors have generated considerable interest in dermatomyositis, where interferon-mediated signalling pathways appear to play a pivotal pathogenic role. Early clinical reports and small case series suggest that JAK inhibition may lead to improvements in both muscle and cutaneous manifestations, particularly in patients with refractory disease. However, the long-term safety and effectiveness of these agents in IIM remain to be fully established<sup>14,15</sup>.

Despite these encouraging developments, several important challenges persist. Perhaps the most fundamental issue is the marked heterogeneity of IIM itself. The spectrum of disease includes polymyositis, dermatomyositis, immune-mediated necrotising myopathy and inclusion body myositis, each with distinct pathological and clinical characteristics<sup>16</sup>. In addition, the identification of myositis-specific autoantibodies has further refined disease classification, revealing subsets associated with particular clinical features, prognostic implications and therapeutic responses.

This increasing complexity highlights the limitations of traditional “one-size-fits-all” treatment approaches. Instead, a more personalised strategy may be required, integrating clinical phenotype, autoantibody profile and organ involvement. Achieving this goal will depend not only on improved understanding of disease mechanisms but also on the development of reliable biomarkers capable of predicting treatment response.

Another persistent obstacle is the limited number of well-designed clinical trials in this field<sup>17</sup>. The rarity of IIM poses significant difficulties in patient recruitment and trial design, often resulting in small sample sizes and heterogeneous study populations<sup>18</sup>. International collaboration and the use of standardised outcome measures will therefore be essential to generate more robust evidence. Initiatives such as collaborative research networks and multinational registries may play a crucial role in addressing these challenges<sup>19–21</sup>.

Importantly, optimal management of IIM extends beyond pharmacological therapy. Multidisciplinary care remains fundamental, particularly given the potential involvement of multiple organ systems. Respiratory disease, interstitial lung disease, cardiac complications and dysphagia may all contribute substantially to morbidity and mortality. Close collaboration between rheumatologists, neurologists, pulmonologists and rehabilitation specialists is therefore essential to ensure comprehensive care.

Rehabilitation and structured exercise programmes also represent key components of management. Historically, concerns were raised regarding the potential exacerbation of muscle inflammation with physical activity. However, accumulating evidence suggests that appropriately supervised exercise can improve muscle strength, endurance and functional capacity without worsening disease activity. Integrating rehabilitation strategies alongside immunosuppressive therapy may therefore enhance long-term outcomes and quality of life<sup>22,23</sup>. Looking forward, advances in translational research are likely to further reshape the treatment landscape of IIM. Increasing insights into the molecular pathways involved in disease pathogenesis—including interferon signalling, complement activation and antibody-mediated mechanisms—may lead to the development of more targeted therapeutic interventions. At the same time, the integration of biomarker-driven approaches and precision medicine strategies may help identify patients most likely to benefit from specific therapies.

Equally important is the growing recognition of patient-centred outcomes. Beyond improvements in muscle strength or laboratory parameters, treatment strategies should also

aim to address fatigue, physical function and overall quality of life. Incorporating patient-reported outcome measures into both clinical trials and routine care will be essential to ensure that therapeutic advances translate into meaningful benefits for those living with these chronic conditions<sup>24–26</sup>.

In conclusion, the treatment of idiopathic inflammatory myopathies is entering a period of significant transformation. While glucocorticoids and conventional immunosuppressants continue to form the backbone of therapy, the emergence of biologic agents, targeted immunomodulators and small-molecule inhibitors is gradually expanding the therapeutic repertoire. However, the complexity and heterogeneity of these disorders demand a more personalised and evidence-based approach. Continued research, international collaboration and improved disease stratification will be crucial to fully realise the potential of these emerging therapies and ultimately improve outcomes for patients with IIM.

## References

1. Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. *Nat Rev Dis Primer*. 2021 Dec 2;7(1):86.  
<https://doi.org/10.1038/s41572-021-00321-x>
2. Paik JJ, Werth VP, Chinoy H, Masri KR, Jambekar A, Hasan F, et al. Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review. *Rheumatology*. 2025 Jun 1;64(6):3288-302.  
<https://doi.org/10.1093/rheumatology/keaf116>
3. Campanilho-Marques R, Fonseca JE, Machado PM. Treatment of idiopathic inflammatory myopathies. *Joint Bone Spine*. 2025 Dec;92(6):105932. 2  
<https://doi.org/10.1016/j.jbspin.2025.105932>
4. Connolly CM, Paik JJ. Clinical pearls and promising therapies in myositis. *Expert Rev Clin Immunol*. 2023 Jul 3;19(7):797-811.  
<https://doi.org/10.1080/1744666X.2023.2212162>
5. Connolly CM, Plomp L, Paik JJ, Allenbach Y. Possible future avenues for myositis therapeutics: DM, IMNM and IBM. *Best Pract Res Clin Rheumatol*. 2022 Jun;36(2):101762.  
<https://doi.org/10.1016/j.berh.2022.101762>
6. Oddis CV, Aggarwal R. Treatment in myositis. *Nat Rev Rheumatol*. 2018 May;14(5):279-89.  
<https://doi.org/10.1038/nrrheum.2018.42>
7. Barsotti S, Lundberg IE. Current Treatment for Myositis. *Curr Treat Options Rheumatol*. 2018 Dec;4(4):299-315.  
<https://doi.org/10.1007/s40674-018-0106-2>
8. Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. *Rheumatology*. 2015 Mar 1;54(3):383-91.  
<https://doi.org/10.1093/rheumatology/keu429>
9. Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. *N Engl J Med*. 2022 Oct 6;387(14):1264-78.  
<https://doi.org/10.1056/NEJMoa2117912>
10. Connolly CM, Paik JJ. Clinical pearls and promising therapies in myositis. *Expert Rev Clin Immunol*. 2023 Jul 3;19(7):797-811.  
<https://doi.org/10.1080/1744666X.2023.2212162>
11. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A

- randomized, placebo-phase trial. *Arthritis Rheum.* 2013 Feb;65(2):314-24.  
<https://doi.org/10.1002/art.37754>
12. Connolly CM, Gupta L, Fujimoto M, Machado PM, Paik JJ. Idiopathic inflammatory myopathies: current insights and future frontiers. *Lancet Rheumatol.* 2024 Feb;6(2):e115-27.  
[https://doi.org/10.1016/S2665-9913\(23\)00322-3](https://doi.org/10.1016/S2665-9913(23)00322-3)
13. Aggarwal R, Pongtarakulpanit N, Sullivan DI, Moghadam-Kia S, Bae SS, Wilkerson J, et al. Abatacept for the treatment of myositis-associated interstitial lung disease. *Rheumatology.* 2025 Dec 1;64(S1):SI156-68.  
<https://doi.org/10.1093/rheumatology/keaf218>
14. Paik JJ, Shneyderman M, Gutierrez-Alamillo L, Albayda J, Tiniakou E, Perin J, et al. Long-term extension study of tofacitinib in refractory dermatomyositis. *Arthritis Rheumatol.* 2022 Feb;74(2):371-2.  
<https://doi.org/10.1002/art.41944>
15. Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, et al. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. *Arthritis Rheumatol.* 2021 May;73(5):858-65.  
<https://doi.org/10.1002/art.41602>
16. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser MD, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Ann Rheum Dis.* 2017 Dec;76(12):1955-64.  
<https://doi.org/10.1136/annrheumdis-2017-212786>
17. Saygin D, Werth V, Paik JJ, Park JK, Needham M, Lundberg IE, et al. Current myositis clinical trials and tribulations. *Ann Rheum Dis.* 2024 Jul;83(7):826-9.  
<https://doi.org/10.1136/ard-2023-224652>
18. Mishra S, Venkatesh M. Rare disease clinical trials in the European Union: navigating regulatory and clinical challenges. *Orphanet J Rare Dis.* 2024 Jul 31;19(1):285.  
<https://doi.org/10.1186/s13023-024-03146-5>
19. De Souza FHC, De Araújo DB, Vilela VS, Bezerra MC, Simões RS, Bernardo WM, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. *Adv Rheumatol.* 2019 Dec;59(1):6.  
<https://doi.org/10.1186/s42358-019-0048-x>
20. Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. *J Dermatol.* 2019 Jan;46(1).  
<https://doi.org/10.1111/1346-8138.14604>
21. Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with

idiopathic inflammatory myopathy. *Rheumatology*. 2022 May 5;61(5):1760-8.

<https://doi.org/10.1093/rheumatology/keac115>

22. Zhang H, Liu Y, Ma J, Li Z. Systematic review of physical exercise for patients with idiopathic inflammatory myopathies. *Nurs Health Sci*. 2021 Jun;23(2):312-24.

<https://doi.org/10.1111/nhs.12817>

23. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. *Arthritis Care Res*. 2007 Jun 15;57(5):768-77.

<https://doi.org/10.1002/art.22780>

24. DiRenzo D, Bingham CO, Mecoli CA. Patient-Reported Outcomes in Adult Idiopathic Inflammatory Myopathies. *Curr Rheumatol Rep*. 2019 Nov;21(11):62.

<https://doi.org/10.1007/s11926-019-0862-5>

25. Rider LG, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, et al. Update on outcome assessment in myositis. *Nat Rev Rheumatol*. 2018 May;14(5):303-18.

<https://doi.org/10.1038/nrrheum.2018.33>

26. Regardt M, Basharat P, Christopher-Stine L, Sarver C, Björn A, Lundberg IE, et al. Patients' Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure - Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12. *J Rheumatol*. 2015 Dec;42(12):2492-5.

<https://doi.org/10.3899/jrheum.141243>